Details of the Drug Metabolized by Drug-Metabolizing Enzyme (DME)

General Information of Drug (ID: DR0722)
Drug Name
Fluphenazine decanoate
Prodrug Info Fluphenazine decanoate is the prodrug of Fluphenazine sulfoxide
Synonyms
Flufenazin; Flufenazina; Flufenazina [DCIT]; Fluorfenazine; Fluorophenazine; Fluorphenazine; Fluphenazine [INN:BAN]; Fluphenazinum; Fluphenazinum [INN-Latin]; Ftorphenazine; Moditen (Tabl or elixir); Pacinol; Phthorphenazine; Prolixin; SQ 4918; Sevinol; Siqualine; Siqualon; Triflumethazine; Vespazine; Yespazine; 10-(3-(2-Hydroxyethyl)piperazinopropyl)-2-(trifluoromethyl)phenothiazine; 2-(4-(3-(2-(trifluoromethyl)-10H-phenothiazin-10-yl)propyl)piperazin-1-yl)ethanol; 69-23-8; HSDB 3334; UNII-S79426A41Z; Dapotum; Elinol; FLUPHENAZINE; Dapotum D; FMU62K1L3C; Flufenazine decanoate; Fluorophenazine decanoate; Fluphenaline decanoate; Fluphenazine O-decanoate; Fluphenazine decanoate; Fluphenazine depot; Modecate; Moditen depot; Prolixin decanoate; SQ 10,733; 2-(4-(3-(2-(Trifluoromethyl)phenothiazin-10-yl)propyl)-1-piperazinyl)ethyl decanoate; 2-[4-[3-[2-(trifluoromethyl)phenothiazin-10-yl]propyl]piperazin-1-yl]ethyl decanoate; 5002-47-1; BRN 0599852; C32H44F3N3O2S; CCRIS 3954; EINECS 225-672-4; NSC 169510; UNII-FMU62K1L3C
Indication Schizophrenia [ICD11: 6A20] Approved [1]
Structure
3D MOL is unavailable 2D MOL
Pharmaceutical Properties Molecular Weight 591.8 Topological Polar Surface Area 61.3
Heavy Atom Count 41 Rotatable Bond Count 16
Hydrogen Bond Donor Count 0 Hydrogen Bond Acceptor Count 9
Cross-matching ID
PubChem CID
3388
PubChem SID
10157 ; 442284 ; 5367841 ; 7847858 ; 8152159 ; 16865942 ; 29222523 ; 48416028 ; 49960438 ; 57321771 ; 75108673 ; 88771022 ; 103770837 ; 103821152 ; 104303368 ; 108136249 ; 117505029 ; 126674203 ; 129480527 ; 134223143 ; 134338575 ; 134338624 ; 134986213 ; 141522722 ; 142679208 ; 144227482 ; 162172916 ; 163134728 ; 175266897 ; 179225767 ; 221672973 ; 223671476 ; 223704746 ; 226426349 ; 241102944
ChEBI ID
CHEBI:5124
CAS Number
5002-47-1
TTD Drug ID
D03NTJ
Formula
C32H44F3N3O2S
Canonical SMILES
CCCCCCCCCC(=O)OCCN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F
InChI
1S/C32H44F3N3O2S/c1-2-3-4-5-6-7-8-14-31(39)40-24-23-37-21-19-36(20-22-37)17-11-18-38-27-12-9-10-13-29(27)41-30-16-15-26(25-28(30)38)32(33,34)35/h9-10,12-13,15-16,25H,2-8,11,14,17-24H2,1H3
InChIKey
VIQCGTZFEYDQMR-UHFFFAOYSA-N
The Metabolic Roadmap of This Drug
The Full List of Drug Metabolites (DM) of This Drug
DM Name DM ID PubChem ID Reaction DM Level REF
Fluphenazine sulfoxide DM004681
3036919
Oxidation - S-oxidation 1 [4]
The Full List of Metabolic Reaction (MR) of This Drug
MR ID Reactant Product MR Type DME REF
MR005030 Fluphenazine decanoate Fluphenazine sulfoxide Oxidation - S-oxidation CYP2D6 [4]
Drug-Metabolizing Enzyme(s) (DME) Metabolizing This Drug
DME Name DME Info Species Uniprot ID EC Number REF
Cytochrome P450 2D6 (CYP2D6) DME0009 Homo sapiens
CP2D6_HUMAN
1.14.14.1
[2]
Unclear metabolic mechanism (DME-unclear) DME1256 Bacteroides sartorii Not Available Not Available [3]
Unclear metabolic mechanism (DME-unclear) DME1265 Escherichia coli Not Available Not Available [3]
Unclear metabolic mechanism (DME-unclear) DME1360 Anaerostipes hadrus Not Available Not Available [3]
Unclear metabolic mechanism (DME-unclear) DME1365 Bacteroides dorei Not Available Not Available [3]
Unclear metabolic mechanism (DME-unclear) DME1384 Bacteroides vulgatus Not Available Not Available [3]
Unclear metabolic mechanism (DME-unclear) DME1393 Blautia hansenii Not Available Not Available [3]
Unclear metabolic mechanism (DME-unclear) DME1427 Eubacterium ventriosum Not Available Not Available [3]
Unclear metabolic mechanism (DME-unclear) DME1445 Parabacteroides distasonis Not Available Not Available [3]
Unclear metabolic mechanism (DME-unclear) DME1449 Prevotella copri Not Available Not Available [3]
Unclear metabolic mechanism (DME-unclear) DME1456 Roseburia intestinalis Not Available Not Available [3]
⏷ Show the Full List of 11  DME(s)
References
1 Fluphenazine Enanthate was approved by FDA. The 2020 official website of the U.S. Food and Drug Administration.
2 Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: preferential inhibition of CYP2D6. Drug Metab Dispos. 1999 Sep;27(9):1078-84.
3 Mapping human microbiome drug metabolism by gut bacteria and their genes. Nature. 2019 Jun;570(7762):462-467.
4 Speculations on the substrate structure-activity relationship (SSAR) of cytochrome P450 enzymes. Biochem Pharmacol. 1992 Dec 1;44(11):2089-98.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.